Odevixibat Treatment in Patients With Fic1 Deficiency: Sustained Efficacy, Particularly in Pruritus, in an Integrated Analysis of Responders (Pedfic 1 and Pedfic 2) | Synapse
March 3, 2026
Odevixibat Treatment in Patients With Fic1 Deficiency: Sustained Efficacy, Particularly in Pruritus, in an Integrated Analysis of Responders (Pedfic 1 and Pedfic 2)
Puntos clave
Sustained efficacy of odevixibat significantly reduces pruritus in patients with FIC1 deficiency.
The integrated analysis highlights responses across both PEDFIC 1 and PEDFIC 2 trials.
Assessment included multiple responder evaluations to ensure comprehensive efficacy measurement.
Findings indicate potential for improved symptom management in FIC1 deficiency, emphasizing the need for ongoing support.
Resumen
Odevixibat Treatment in Patients With Fic1 Deficiency: Sustained Efficacy, Particularly in Pruritus, in an Integrated Analysis of Responders (Pedfic 1 and Pedfic 2)